Q-omics provides the consensus-scored PRAMEF17 profile across patient tissues and cancer cell-line models. PRAMEF17 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PRAMEF17 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, PRAMEF17 RNA expression shows 6,669 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, HNSC, and STAD as cancer lineages where PRAMEF17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF17 survival associations across molecular data types. PRAMEF17 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF17 RNA expression–survival associations across cancer types. High PRAMEF17 expression shows unfavorable associations in KICH, MESO, KIRC, LUSC and SCLC, but favorable associations in LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PRAMEF17 RNA expression.
This table summarizes PRAMEF17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF17 shows higher tumor expression in HNSC. The HNSC box plot shows higher PRAMEF17 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .024).
This table shows molecular features associated with PRAMEF17 in patient tissues and cancer cell lines. In patient samples, PRAMEF17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
